{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T02:47:07Z","timestamp":1782701227545,"version":"3.54.5"},"reference-count":41,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/objective: Given the increasing complexity of the luminal breast cancer landscape, a proper characterization is required in everyday clinical practice, and the recurrence after the standard first-line treatment with CDK4\/6 inhibitors with\/without endocrine therapy should be managed. Method: The Hermione Exchange Educational Program was held in Milan, Italy, between September 2024 and January 2025. Two questionnaires were proposed regarding the use of targeted treatment or chemotherapy after progression from CDK4\/6 inhibitors. The lecture and use cases enhanced the discussion during the workshops. Results: From the surveys, it emerged that most participants (69%) considered liver metastases at CDK4\/6-inhibitor progression as a key reason to initiate chemotherapy, while lung progression influenced this choice for 50% of participants. Liver involvement guided the use of targeted therapy for 56%, and attitudes were divided on whether the duration of first-line CDK4\/6 therapy should affect decisions (44% in agreement vs. 38% in disagreement). The willingness of patients to receive chemotherapy (88%) and comorbidities (81%) were significant drivers. Almost all participants agreed that both the duration of response and the molecular status were key aspects to consider when choosing a second line of therapy, along with the general clinical condition of the patient. In the lecture, tissue and liquid biopsy are considered powerful tools to describe tumor molecular features over time; such complexity should be harnessed by a close dialogue between oncologists, molecular biologists, and pathologists to optimize the therapeutic choice according to the mutational status of patients. The use cases illustrate three patients with visceral progression, non-visceral progression within 12 months, and non-visceral progression after 12 months following CDK4\/6 inhibitors. Conclusion: Genomic testing should be considered at diagnosis and repeated during treatment to monitor the disease. The clinical experience acquired over the years must be integrated with new molecular knowledge.<\/jats:p>","DOI":"10.3390\/cancers18132087","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T02:16:44Z","timestamp":1782699404000},"page":"2087","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hermione Exchange Educational Program: How to Integrate Multidisciplinary Approaches to Manage HR+\/HER2- Metastatic Breast Cancer"],"prefix":"10.3390","volume":"18","author":[{"given":"Marina Elena","family":"Cazzaniga","sequence":"first","affiliation":[{"name":"Phase 1 Research Unit, Fondazione IRCCS San Gerardo dei Tintori, 20900 Monza, Italy"},{"name":"Dipartimento di Medicina e Chirurgia, Universit\u00e0 degli Studi Milano Bicocca, 20126 Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Fusco","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina e Chirurgia, Universit\u00e0 degli Studi Milano Statale, 20122 Milano, Italy"},{"name":"European Oncology Institute, 20141 Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0758-8033","authenticated-orcid":false,"given":"Alessandra","family":"Fabi","sequence":"additional","affiliation":[{"name":"Policlinico Gemelli, 00168 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3211-9957","authenticated-orcid":false,"given":"Umberto","family":"Malapelle","sequence":"additional","affiliation":[{"name":"Dipartimento di Sanit\u00e0 Pubblica, Universit\u00e0 degli Studi Federico II, 80138 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Vigneri","sequence":"additional","affiliation":[{"name":"Oncology Unit, Humanitas Catania, 95045 Catania, Italy"},{"name":"Oncology Unit, Humanitas University, 20089 Rozzano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"key":"ref_1","unstructured":"AIRTUM (2026, June 20). I numeri del Cancro 2025. Available online: https:\/\/www.aiom.it\/wp-content\/uploads\/2025\/12\/2025_NDC_web.pdf."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"de Azambuja, E., Barrios, C.H., Bartsch, R., Curigliano, G., Dent, R., Gennari, A., Loi, S., Paluch-Shimon, S., Pistilli, B., and Saura, C. (2026). Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol., S0923-7534(26)00902-6.","DOI":"10.1016\/j.annonc.2026.05.707"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"691","DOI":"10.6004\/jnccn.2022.0030","article-title":"Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Gradishar","year":"2022","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mce.2017.08.011","article-title":"Estrogen and progesterone signalling in the normal breast and its implications for cancer development","volume":"466","author":"Hilton","year":"2018","journal-title":"Mol. Cell Endocrinol."},{"key":"ref_6","first-page":"525","article-title":"Diagnostic and Prognostic Biomarkers of Luminal Breast Cancer: Where are We Now?","volume":"15","author":"Ring","year":"2023","journal-title":"Breast Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Zhang, L., Sun, F., Wang, X., Zhao, W., Jia, Y., Wang, H., Han, Y., and Tong, Z. (2026). Efficacy and safety of treatments in HR+\/HER2- advanced breast cancer after CDK4\/6 inhibitor progression: A network meta-analysis and scoping review. BMC Cancer, 26.","DOI":"10.1186\/s12885-026-15632-z"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"104831","DOI":"10.1016\/j.breast.2026.104831","article-title":"New perspectives on endocrine therapy suitability for hormone receptor-positive metastatic breast cancer in clinical practice","volume":"88","author":"Rugo","year":"2026","journal-title":"Breast"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Verret, B., Bottosso, M., Hervais, S., and Pistilli, B. (2022). The Molecular Predictive and Prognostic Biomarkers in Metastatic Breast Cancer: The Contribution of Molecular Profiling. Cancers, 14.","DOI":"10.3390\/cancers14174203"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-Mutated, Hormone Receptor\u2013Positive Advanced Breast Cancer","volume":"380","author":"Ciruelos","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"103535","DOI":"10.1016\/j.eclinm.2025.103535","article-title":"Efficacy and safety of systemic therapies following progression on CDK4\/6 inhibitors in HR+\/HER2- metastatic breast cancer: A systematic review and network meta-analysis","volume":"89","author":"Buonaiuto","year":"2025","journal-title":"eClinicalMedicine"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"176424","DOI":"10.1016\/j.ejphar.2024.176424","article-title":"Pharmacological insights on novel oral selective estrogen receptor degraders in breast cancer","volume":"969","author":"Guglielmi","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1056\/NEJMoa2502929","article-title":"First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer","volume":"393","author":"Bidard","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"100882","DOI":"10.1016\/j.esmoop.2023.100882","article-title":"How I treat endocrine-dependent metastatic breast cancer","volume":"8","author":"Gombos","year":"2023","journal-title":"ESMO Open"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_16","first-page":"1431","article-title":"Predicting resistance to endocrine therapy in breast cancer: It\u2019s time for epigenetic biomarkers","volume":"41","author":"Amorim","year":"2019","journal-title":"Oncol. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1158\/1541-7786.MCR-14-0195","article-title":"Delineation of a FOXA1\/ER\u03b1\/AGR2 regulatory loop that is dysregulated in endocrine therapy-resistant breast cancer","volume":"12","author":"Wright","year":"2014","journal-title":"Mol. Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Raheem, F., Karikalan, S.A., Batalini, F., El Masry, A., and Mina, L. (2023). Metastatic ER+ Breast Cancer: Mechanisms of Resistance and Future Therapeutic Approaches. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242216198"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1200\/JCO.24.00427","article-title":"FDA Approval Summary: Capivasertib With Fulvestrant for HR-Positive, HER2-Negative Advanced Breast Cancer With PIK3CA\/AKT1\/PTEN Alterations","volume":"42","author":"Dilawari","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Pescia, C., Guerini-Rocco, E., Viale, G., and Fusco, N. (2023). Advances in Early Breast Cancer Risk Profiling: From Histopathology to Molecular Technologies. Cancers, 15.","DOI":"10.3390\/cancers15225430"},{"key":"ref_22","first-page":"1235","article-title":"Assessment of estrogen receptor low positive status in breast cancer: Implications for pathologists and oncologists","volume":"36","author":"Fusco","year":"2021","journal-title":"Histol. Histopathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO\/CAP Guideline Update","volume":"38","author":"Allison","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/his.14786","article-title":"An update on the pathological classification of breast cancer","volume":"82","author":"Rakha","year":"2023","journal-title":"Histopathology"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Urso, L., Vernaci, G., Carlet, J., Lo Mele, M., Fassan, M., Zulato, E., Faggioni, G., Menichetti, A., Di Liso, E., and Griguolo, G. (2021). ESR1 Gene Mutation in HR-Positive HER2-Negative Metastatic Breast Cancer: Concordance Between Tumor Tissue and ctDNA. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.625636"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"100164","DOI":"10.1016\/j.esmoop.2021.100164","article-title":"Molecular profiling of solid tumors by liquid biopsy: Position paper of Italian Scientific Societies","volume":"6","author":"Russo","year":"2021","journal-title":"ESMO Open"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1158\/0008-5472.CAN-21-2576","article-title":"Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis","volume":"82","author":"Li","year":"2022","journal-title":"Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.2147\/CMAR.S173193","article-title":"Clinical value of circulating ESR1 mutations for patients with metastatic breast cancer: A meta-analysis","volume":"10","author":"Zhang","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant Versus Standard Endocrine Therapy for ER-Positive, HER2-Negative Advanced Breast Cancer: EMERALD Trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1158\/1078-0432.CCR-24-1073","article-title":"Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from EMERALD","volume":"30","author":"Bardia","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6297","DOI":"10.1021\/acs.analchem.2c00446","article-title":"Real-Time Detection of ESR1 Mutation in Blood by ddPCR in PADA-1: Feasibility and Cross-Validation with NGS","volume":"94","author":"Callens","year":"2022","journal-title":"Anal. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Venetis, K., Pepe, F., Munzone, E., Sajjadi, E., Russo, G., Pisapia, P., Ivanova, M., Bonizzi, G., Vacirca, D., and Rappa, A. (2022). Analytical Performance of NGS and RT-PCR on FFPE Tumor Tissues for PIK3CA Testing in HR+\/HER2- Breast Cancer. Cells, 11.","DOI":"10.3390\/cells11223545"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.annonc.2020.11.011","article-title":"Alpelisib plus fulvestrant for PIK3CA-mutated HR+\/HER2- advanced breast cancer: Final OS results from SOLAR-1","volume":"32","author":"Ciruelos","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Fusco, N., Malapelle, U., Fassan, M., Marchi\u00f2, C., Buglioni, S., Zupo, S., Criscitiello, C., Vigneri, P., Dei Tos, A.P., and Maiorano, E. (2021). PIK3CA Mutations as a Molecular Target for HR+\/HER2- Metastatic Breast Cancer. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.644737"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2217\/pgs-2023-0238","article-title":"PIK3CA testing in HR+\/HER2- metastatic breast cancer: Real-world data from Italian laboratories","volume":"25","author":"Pepe","year":"2024","journal-title":"Pharmacogenomics"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1158\/1078-0432.CCR-25-3040","article-title":"Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-Mutant Metastatic Breast Cancer","volume":"32","author":"Rugo","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1158\/2159-8290.CD-20-1647","article-title":"Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA","volume":"11","author":"Aftimos","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2217\/fon-2022-1196","article-title":"Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer","volume":"19","author":"Turner","year":"2023","journal-title":"Future Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/14622416.2026.2658438","article-title":"The use of cfDNA\/ctDNA to guide treatment selection in metastatic breast cancer","volume":"27","author":"Bello","year":"2026","journal-title":"Pharmacogenomics"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1158\/2159-8290.CD-18-0264","article-title":"Genetic Landscape and Clonal Evolution of Resistance to Palbociclib plus Fulvestrant in PALOMA-3","volume":"8","author":"Cutts","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1158\/1078-0432.CCR-25-3033","article-title":"Clinical and Genomic Factors Associated with Elacestrant Outcomes in ESR1-Mutant Metastatic Breast Cancer","volume":"32","author":"Lloyd","year":"2026","journal-title":"Clin. Cancer Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/13\/2087\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T02:39:47Z","timestamp":1782700787000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/13\/2087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":41,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cancers18132087"],"URL":"https:\/\/doi.org\/10.3390\/cancers18132087","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]}}}